Doxazosin and congestive heart failure

Area of Science:

• Cardiology
• Pharmacology
• Hypertension Research

Background:

• Long-standing hypertension is a major risk factor for congestive heart failure (CHF).
• The Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) investigated treatments for hypertension.
• Previous studies indicated a link between antihypertensive medications and CHF risk.

Purpose of the Study:

• To evaluate the comparative risk of congestive heart failure (CHF) associated with different antihypertensive medications.
• To determine if alpha-blockers pose a higher risk for CHF compared to diuretics.
• To inform first-line treatment recommendations for hypertension based on CHF risk.

Main Methods:

• Analysis of data from the Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).
• Comparison of congestive heart failure (CHF) incidence between patients treated with doxazosin (an alpha-blocker) and chlorthalidone (a diuretic).
• Assessment of cardiac and overall mortality in relation to treatment arms.

Main Results:

• The risk of congestive heart failure (CHF) was found to be twice as high in patients treated with doxazosin compared to chlorthalidone.
• The ALLHAT trial provided significant data on the differential risk of CHF between these antihypertensive drug classes.
• Some uncertainties remain regarding CHF diagnosis and malignancy risk in specific ALLHAT arms.

Conclusions:

• Doxazosin, and potentially all alpha-blockers, demonstrated an increased risk for congestive heart failure (CHF).
• Current evidence suggests alpha-blockers should not be considered a first-line therapy for hypertension.
• Further safety data are required before reconsidering the use of alpha-blockers in initial hypertension management.